Ipsen and Marengo Therapeutics, Inc. entered a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization.   Ipsen will make an upfront payment of $45 million, together with potential payments of as much as $1.59 billion if all milestones are met in addit...